Amylyx Pharmaceuticals Appoints New Directors, Updates Executive Compensation
Ticker: AMLX · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1658551
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
Amylyx adds two board members and finalizes exec pay packages for CEO & CMO.
AI Summary
Amylyx Pharmaceuticals, Inc. announced on March 14, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Albert Eschenmoser and Dr. David J. Ebersman, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Joshua Allen, and Chief Medical Officer, Dr. Sabrina Paganoni, detailing their compensation packages.
Why It Matters
The appointment of new directors and updates to executive compensation can signal strategic shifts or confidence in leadership, potentially impacting investor sentiment and the company's future direction.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance changes and executive compensation, which typically carry low immediate risk.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- Dr. Albert Eschenmoser (person) — Newly elected Director
- Dr. David J. Ebersman (person) — Newly elected Director
- Joshua Allen (person) — Chief Executive Officer
- Dr. Sabrina Paganoni (person) — Chief Medical Officer
- March 14, 2024 (date) — Date of Report
FAQ
Who were the new directors elected to Amylyx Pharmaceuticals' Board?
Dr. Albert Eschenmoser and Dr. David J. Ebersman were elected as new directors to the Board of Directors of Amylyx Pharmaceuticals, Inc.
What is the date of this Form 8-K filing?
The Form 8-K filing is dated March 14, 2024.
What are the main items reported in this 8-K filing?
This filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the principal executive office address for Amylyx Pharmaceuticals?
The principal executive offices are located at 43 Thorndike St., Cambridge, MA 02141.
Who are the key executives whose compensatory arrangements are mentioned?
The filing mentions new employment agreements with Chief Executive Officer Joshua Allen and Chief Medical Officer Dr. Sabrina Paganoni.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-03-14 09:18:53
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
- $45,000 — igible to receive an annual retainer of $45,000 for serving on the Board, and an additi
- $5,000 — d, and an additional annual retainer of $5,000 for serving on the Nominating Committee
- $570,000 — r of (x) a stock option with a value of $570,000, and (y) a stock option to purchase 50,
- $285,000 — r of (x) a stock option with a value of $285,000, and (y) a stock option to purchase 25,
Filing Documents
- d789002d8k.htm (8-K) — 26KB
- 0001193125-24-067471.txt ( ) — 142KB
- amlx-20240314.xsd (EX-101.SCH) — 3KB
- amlx-20240314_lab.xml (EX-101.LAB) — 17KB
- amlx-20240314_pre.xml (EX-101.PRE) — 11KB
- d789002d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: March 14, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer